A glimpse of the Branded Generics Market: Drivers and Opportunities

The off-patented medicines sold under a brand name that offer significant benefits to patients and medical professionals are referred to as branded generics. They are pharmaceutical drug molecules equivalent to generic healthcare products differentiated from them with the help of the brand name they are marketed under. There is significant rivalry witnessed between the generic drugs and the branded generic drugs.

Branded generics are witnessing effective application in the treatment of neurological, gastrointestinal, cardiovascular, dermatology, oncology, anti-inflammatory diseases, and others. Out of all these diseases, there is a significantly more visibility of branded generics in oncology therapeutic application.

Branded Generic Drugs: Resulting in an emerging market of the future

 Despite being more expensive, branded generics do not bargain on the quality of drugs given to patients. These are being used in the treatment of various chronic illnesses and help prevent the diseases with more precision and quality. With effective control on a disorder like leukemia, branded generics are becoming an effective healthcare solution. Advancements in disease treatment with the help of a single drug was a revolution in itself. Branded generics are, therefore, constantly taking efforts towards delivering cost-effective drugs, along with supreme quality and extensive accessibility.

 The conventional generic drugs in comparison could not deliver this quality in spite of them being more affordable and accessible. In diseases like cancer, patients are seen depending on medicines for a prolonged period of time, creating a burden on the patients. In such cases, drugs like branded generics are an effective measure for treatment of these diseases. When it comes to safeguarding the lives of patients, branded generics is the best approach for universal healthcare according to the chairman of Medical and Haemato Oncology, Cancer Institute, Medanta. The idea of bringing quality, availability, affordability, and accessibility in healthcare is largely supported by the future opportunities that branded generics hold.

Pharmaceuticals and drug manufacturing companies to leverage the potential of branded generic drugs

Branded generics are heading to be one of the most lucrative sectors, due to which the drug manufacturers are gradually inclining towards this idea of repackaging and marketing generic drugs as branded generics. Abbott Laboratories, an American healthcare brand is paving its way in the branded generics market, by introducing their healthcare products. The laxative gummy bears, called ‘Duphabears’ are a contribution to the market, which showcases the growing significance of branded generics market.

These are exclusively being introduced in Russia, the Middle-East and Africa, Eastern Europe and Asia which is a large consumer of branded generic drugs. In fact, Abbott is amongst the top five companies in Russia for branded generic drugs. It has shifted its focus towards branded generics making it a current priority and one its latest acquisition of CFR Pharmaceuticals back in 2014 for the expansion of its branded generics presence in Latin America is a key highlighter of the growth opportunities possessed by the branded generics market. Abbott was also seen diversifying their business a year later. It divested the business of branded generics in developed and emerging regions to capitalize the branded generics market of growing countries. With key players indulging in expansion strategies, the branded generics market is sure to witness an elevation in the coming future.

Opportunities and trends shaping the future of the branded generics market

With the quality of the drugs falling under the category of branded generics market are achieving more value in the coming future. Its therapeutic application in the field of oncology is gaining more prominence especially due to the growing cases of cancer patients with respect to a global scenario. The rising cases of diabetes and cardiovascular diseases are creating sufficient opportunities for the escalation of the market. With more pharmaceutical companies inclining towards producing branded generic drugs, there is a possibility of more players to enter the global branded generics market. Amongst these, the cardiovascular disease segment is expected to dominate the market through the entire current decade. Additionally, the oncology segment is also seen on a consistent stability.

Demand for branded generic medicines and drugs in increasing due to the rising regulations and affordability of products. In addition to this, there are numerous differentiation strategies implemented by the drug manufacturers where various pharmaceutical companies are offering off-patented branded generics, which is expected to drive the market growth. Along with these factors, the increasing purchasing power of potential patients and the rising prevalence of chronic disorders is expected to fuel the branded generics market in the future.